Where can the blood concentration of Mitotane be tested accurately?

Mitotane (Mitotane) is a special anti-tumor drug used to treat adrenocortical cancer (ACC). Due to its narrow therapeutic window and large individual differences, it is usually necessary to monitor blood drug concentrations in clinical practice to ensure drug efficacy and reduce toxic reactions. Accurate blood concentration testing is crucial to guide mitotane treatment. The following describes the testing location, operating procedures, testing institution qualifications, and patient precautions.

The most common and reliable way to conduct mitotane blood concentration testing is through the clinical pharmacology laboratory or pharmacy department of a qualified tertiary hospital. Especially for large general hospitals or specialized cancer hospitals, such as the Cancer Hospital of the Chinese Academy of Medical Sciences, Peking Union Medical College Hospital, and Shanghai Cancer Hospital of Fudan University, some hospitals have clinical drug concentration monitoring (TDM) services that can provide concentration testing of specific targeted drugs, including mitotane.

For patients who have limited testing resources in some areas or whose hospitals are unable to carry out this testing project, their doctors can apply for external testing and send their blood samples to qualified third-party medical testing institutions. For example, some well-known medical testing laboratories in China, such as Jinyu Medical, Aidicon, and Dean Diagnostics, can provide mitotane blood concentration testing services in some areas. These institutions usually have established cooperative networks with multiple hospitals, and the test results are also highly accurate and authoritative.

Detection of mitotane plasma concentration usually uses high-performance liquid chromatography (HPLC) or mass spectrometry (LC-MS/MS) and other technologies, which have higher requirements on experimental conditions and operating specifications. Therefore, it is recommended to choose a laboratory with relevant experience and complete equipment for operation to ensure reliable results. Before testing, patients need to follow the doctor's guidance to accurately control the timing of drug withdrawal or blood collection. It is usually recommended to collect blood during the steady state period of medication (i.e. after 2-3 weeks of continuous medication) so that the results can have more clinical reference value.

When preparing for blood drug concentration testing, patients need to communicate with the attending doctor in advance, who will determine whether testing is necessary and the sampling time. After the test results come out, the doctor will determine whether the blood drug concentration reaches the therapeutic range (usually 14–20 mg/L) to adjust the dosage to achieve the best therapeutic effect. Regular blood concentration monitoring is crucial for individualized treatment of mitotane. Especially in the early treatment stage or during dose adjustment, more attention should be paid to the timeliness and accuracy of detection.

Reference materials:https://go.drugbank.com/drugs/DB00648